|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: S100A6 |
Gene summary for S100A6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | S100A6 | Gene ID | 6277 |
| Gene name | S100 calcium binding protein A6 | |
| Gene Alias | 2A9 | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P06703 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6277 | S100A6 | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 3.29e-14 | -1.53e+00 | 0.156 |
| 6277 | S100A6 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 6.02e-19 | -1.49e+00 | 0.1479 |
| 6277 | S100A6 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 1.56e-24 | -1.77e+00 | 0.1531 |
| 6277 | S100A6 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 8.29e-55 | -1.27e+00 | 0.1633 |
| 6277 | S100A6 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 5.05e-64 | -1.21e+00 | 0.1608 |
| 6277 | S100A6 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 3.99e-45 | -1.18e+00 | 0.1604 |
| 6277 | S100A6 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 9.26e-46 | -1.05e+00 | 0.1621 |
| 6277 | S100A6 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 8.41e-32 | -1.46e+00 | 0.1619 |
| 6277 | S100A6 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 3.12e-25 | -1.54e+00 | 0.159 |
| 6277 | S100A6 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.21e-49 | -1.27e+00 | 0.1602 |
| 6277 | S100A6 | GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004 | Human | Prostate | Tumor | 1.41e-15 | -1.61e+00 | 0.1537 |
| 6277 | S100A6 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 9.75e-22 | -1.70e+00 | 0.1439 |
| 6277 | S100A6 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 1.73e-34 | -1.48e+00 | 0.1608 |
| 6277 | S100A6 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 3.43e-26 | -1.53e+00 | 0.1622 |
| 6277 | S100A6 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 3.14e-67 | -1.21e+00 | 0.1575 |
| 6277 | S100A6 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.44e-85 | -1.70e+00 | 0.1545 |
| 6277 | S100A6 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.34e-73 | -1.68e+00 | 0.1569 |
| 6277 | S100A6 | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 3.67e-14 | -1.63e+00 | 0.1532 |
| 6277 | S100A6 | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 5.49e-14 | -1.18e+00 | 0.1541 |
| 6277 | S100A6 | P1_S1_AK | Human | Skin | AK | 6.39e-52 | -6.50e-01 | -0.3399 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00481453 | Breast | Precancer | regulation of fibroblast proliferation | 12/1080 | 80/18723 | 2.03e-03 | 1.94e-02 | 12 |
| GO:00481443 | Breast | Precancer | fibroblast proliferation | 12/1080 | 81/18723 | 2.26e-03 | 2.12e-02 | 12 |
| GO:004814511 | Breast | IDC | regulation of fibroblast proliferation | 14/1434 | 80/18723 | 2.83e-03 | 2.48e-02 | 14 |
| GO:004814411 | Breast | IDC | fibroblast proliferation | 14/1434 | 81/18723 | 3.18e-03 | 2.68e-02 | 14 |
| GO:00481452 | Breast | DCIS | regulation of fibroblast proliferation | 13/1390 | 80/18723 | 5.80e-03 | 4.17e-02 | 13 |
| GO:00481442 | Breast | DCIS | fibroblast proliferation | 13/1390 | 81/18723 | 6.45e-03 | 4.58e-02 | 13 |
| GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
| GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
| GO:00481462 | Cervix | HSIL_HPV | positive regulation of fibroblast proliferation | 7/737 | 48/18723 | 2.57e-03 | 2.50e-02 | 7 |
| GO:00481454 | Cervix | HSIL_HPV | regulation of fibroblast proliferation | 9/737 | 80/18723 | 4.13e-03 | 3.53e-02 | 9 |
| GO:00481444 | Cervix | HSIL_HPV | fibroblast proliferation | 9/737 | 81/18723 | 4.49e-03 | 3.76e-02 | 9 |
| GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
| GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
| GO:00615641 | Colorectum | SER | axon development | 94/2897 | 467/18723 | 3.78e-03 | 3.13e-02 | 94 |
| GO:00074091 | Colorectum | SER | axonogenesis | 84/2897 | 418/18723 | 6.20e-03 | 4.49e-02 | 84 |
| GO:00074092 | Colorectum | MSS | axonogenesis | 105/3467 | 418/18723 | 4.32e-04 | 5.23e-03 | 105 |
| GO:00615642 | Colorectum | MSS | axon development | 115/3467 | 467/18723 | 5.33e-04 | 6.00e-03 | 115 |
| GO:00615643 | Colorectum | FAP | axon development | 106/2622 | 467/18723 | 1.98e-07 | 1.21e-05 | 106 |
| GO:00074093 | Colorectum | FAP | axonogenesis | 97/2622 | 418/18723 | 2.20e-07 | 1.30e-05 | 97 |
| GO:00074094 | Colorectum | CRC | axonogenesis | 81/2078 | 418/18723 | 3.60e-07 | 2.99e-05 | 81 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| S100A6 | SNV | Missense_Mutation | c.172N>A | p.Glu58Lys | p.E58K | P06703 | protein_coding | tolerated(1) | benign(0.007) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| S100A6 | insertion | Frame_Shift_Ins | novel | c.238_239insCACGGTCAACCTCTGAAAA | p.Leu80SerfsTer13 | p.L80Sfs*13 | P06703 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| S100A6 | SNV | Missense_Mutation | novel | c.221N>C | p.Val74Ala | p.V74A | P06703 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| S100A6 | SNV | Missense_Mutation | novel | c.22G>A | p.Ala8Thr | p.A8T | P06703 | protein_coding | deleterious(0.04) | possibly_damaging(0.865) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| S100A6 | SNV | Missense_Mutation | c.192N>T | p.Lys64Asn | p.K64N | P06703 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-BR-8081-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| S100A6 | SNV | Missense_Mutation | novel | c.67N>A | p.Glu23Lys | p.E23K | P06703 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-BR-8362-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD |
| S100A6 | SNV | Missense_Mutation | c.32T>G | p.Leu11Arg | p.L11R | P06703 | protein_coding | deleterious(0.02) | benign(0.42) | TCGA-EM-A3AK-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |